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This thesis presents prognostic f 'actors, survival and latc mortal i ty of paticnts with
Hoclgkin's lyrnphonra diagnosed in South-East Nctherlands.
Chapter I  consists of an ovcrview of epidemiology, pathogenesis, cl inical presentation,
nranagcmcnt and i ts complications of Hodgkin's lymphoma (HL). HL can be diagnosed
hased on i ts typical histological picture with pathognomonic mult inucleated Reed-
Stelnherg (RS) cel ls ancl Hoclgkin (H) ccl ls, the mononuclear variants. Accumulating data
sr-rggesl t l .ral these cel ls originate f}om gcrminal-center B cel ls and their dcscendants,
rvhich Lrnclerwent a translbrrning cvcr.rt  (EBV int 'ect ion?), enabling theln to escape
apoptotic ccl l  cleath. EBV-related protcins and mRNA have been detectcd in the H-RS
cells of 25(;/ i  to -507i, of HL patients in the developed countr ics and up fo10% to 1007o in
the cicveloping countr ies. EBV is known to be a highly potent transfbrming agent in B-
lymphocytes. rvhich is norrnal ly control led by a cytotoxic T-lvmphocyte mediated
inmunc rcsponsc, which fai ls in patients r 'vi th HL. This tai lure may bc due to several
rnechanisms inclucl ing down rcgulat ion of MHC class I antigens on the H-RS-cel ls and
the  produc t ion  o f  inh ib i t ing  cv tok ines ,  ( IL -10  and TGF- [ ] )  by  thc  H-RS ce l l s .  More  than
9-57r of thc ccl ls in HL involvcci t issuc consist of reacl ive cel ls and the rna.jori ty of the
inf i l trat ing lynrphocytes cl isplay a ' Ih2-l ike irr imunophenotypc. These Th2 cel ls are
plobably attfacted by thc chcmokine TARC, ploduccci by the H-RS cel ls. Thc Ryc
histological classif icat ion of HL as uscd in this thcsis is based on the variat ion of the
cel lular inf i l t ratc rccognizing 4 subtypes: lymphocytc predominant, nodular sclerosis,
rnixcd cclh-r lari ty and l l ,mphocyte dcplct ion. Thc staging systcm is based on the
biological behavior of contiguous spread. in which early stage disease is confined to
l l ,rnph nodc in'u'olvement on one side of the diaphri igm. I f  patients with HL are not treated
thev have a 5-year sr-rn' ival ol '  less than -59{,.  Paticnts with early stage HL general ly
rcccivccl radiothcrapv. but recent studies indicate the benell t  of (adjuvant) chemotherapy
in dcl inccl patient-groups. in conjunction with lower radiat ion dose and smallcr f ields to
nrinimizc toxicity. Patients rvith aclvanced disease should rcccivc chemotherapy ancl thc
role of adj irvant radiothelapv is controversial,  cxcept for patients prescnting with a large
nrccl iast inal rnass. Long tcrm surr" ivors have an increased incidence of several diseases of
which sccond malignancies and cardiac diseases are thc nrost f 'eared. Cured HL patients
sult-cr from an inclcascd cleath-r isk and thcrcf i)re one of the nra.jor goals clf  ncw treatment
strategies is to rninimiz.e toxicity rvi th preservation ol 'el ' f icacy.
Although cl inical tr ials are essential 1br the developmcnt of nc\\ '  trcatment strategie s, thc
application of those stratcgics in the gencral health care environmcnt citn give addit ional
ploof o1'thcir cff icacy. sal-ety and uti l i ty. This is of part icular interest sincc the results of
cl inical tr ials, with thcir rcstr icl ive el igibi l i ty cr i tcr ia, n.ray be biased f l 'om those in the
gcncral popr-r lat ion, which is l ikcly to comprise rnore elderly ancl more patients with poor
pcrf irrntancc status ancl/or sel ious co-rnorbicl i ty. Chapter 3 describes the presentation,
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treatment pol icy and results of al l  patients diagnosecl with I"IL over a 20 ycar period in the
region of the Eindhoven Canccr Registry. covc-r ing almost or.rc rni l l ion inhabitants. The
stLrdy, in fact an audit study, was started in 1983, when douhf arosc on the treatntenl
approach. The crude incidence (1.9 per 100.000 person-years) remaincd stablc over this
period and is cornparable with inciclence rates in other developed countr ies. Likewise, the
mean age (38-4 I yr.) and the pcrcentage of 'patients presenting with early stage discase
(597o) remained stable over this period. Aftcl  rcview ol ' the histology 4o/a ct l  thc- registerecl
f {odgk in  cases .  d iagnosed in  the  1970s,  u 'e re  rec lass i l i cd  l s  non-Hodgk in 's  l ynrphonr l .
Paticnts were diagnc'rsed and treated in l0 commr.rnity hospitals and the re gional
Radiotherapy Department. From 1979 the staging and therapcutic pol icy was, in most
cases. discussed in the regular regional mult idiscipl inary rneetings. This stLrdy gloup
part icipated in the cl inical tr ials of the EORTC fiom l9Ul. Ovcr the 20-year period the
management ol '  ne',vly HL patients changcd, lbl lowing dcveloping insights ancl in
accordance rvith the treatment advocatcd bv the EORTC tr ials. In gencral paticnts with
\tagcs IA and l lA received rnantle-f leld or invertcd Y-f ield irradiat ion, whereas patients
r, i ' i th stages IB and IIB received more extcnsive irradiat ion with or withoLrt chemothcrapy.
Paticnts with aclr 'anced discase (stage II I  and IV) receivecl chcmotherapr,.  f l 'equcntly
f ir l lor.vcd by involved f ield irracl i l t ion. Thc percentrge of 'patients receiving thc ertcnsive
subtotal norlal i rradiat ion (STNI) clecl incd f lom 5f)% in thc early 1970s tou'ards l4%, i t ' t
t l rc latc 1980s. Likewise, the use of thc NlOPP-chemotherapy decleascrl  ihn 50%
towards l07c and was mainly replaccd by MOPP/ABV. The perccntage clf 'patients
achieving complcte remission increased l iom l2% tor.vards 8t)7c ancl the 5-vcar survival
ratcs improved signif icantly fronr 607c to 8l%,. u' i th the greatcst benefi t  in the elcicr ly. At
nr r r l t i va r ia te  ana lys is  advanced l rge .  advanccd s tagc  anc l  h is to logy  har l  indcpendcnt
advcrse prognosl ic valuc. Pcl iod ot 'cl iagnosis t l91l0s) was also of indcpcndcnt far"oLrrablc
prognost ic  va luc  in  the  samc ana lvs is .  Re la t i vc  surv iva l  ( thc  ra t io  o f  the  c ruc le  1o  the
cxpected sr.rrvival in the general populat ion) is an estimatc of rnortal i ty attr ibutablc to the
discase studicd. providccl thut the study cohort doe s rrot cl i l ' l 'cr 1l 'orn tht- genelal
popu la t ion .  as  i s  thc  c lsc  in  th rs  t l ' r cs is .  The lc la t i ve  s i i l v i va l  o t '  I JL  pa t ien ts  a lso
irnproved signi l icantly ovcr thc 20-ycar pel iocl studied, thus el inr inating thc conlbr,rnding
cltcct of conrpeting death-r ' isk and incrcasing l i l 'c cxpectancv in lhe general populat ion.
The results at rnult ivariate analysis ancl the irnprclvecl rclat ive' survival indicate that the
obsen'ed improvement in survival of HL paticnts in Sctuth-East Nethcrlands is
inc lcpendent  o f  t l i scasc- re la te< l  chanrc te r is t i cs  ( \ tage.  h is to logy)  anc l  pu t ien t - rc la (ec l
clraracterist ics ( lgc, gcncler) ancl thcrelorc nru\t be ascribed to thc chanucrl t fei l tmcnt-
po l i cy  in  th is  reg ion .
The treatment results in the regron eqLral lcd those obtainccl in ref-erral centrcs, givine
cvidcnce thar treatment of HI- is l 'e asible in conrrnunity hospitals. proviclecl that qual i tv o1'
care  is  guarantccc l  b1 ,a  good rnLr l t i i l i sc ip l i r r l r ' \ ' co l labora t ion .  Iu rpor tan t  c ( )n tponents  o l
such an approach arc part icipation in cl inical tr ials and the l l 'att tewolk of a
comprchensive cancer centrc.
Thc increasing awarcncss of long-terrn trcatrnent-relatcd toxlcity has lccl to appl ical ion
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of less aegressive therapv. In chapter 4 this lrend was also observed in the study-
populat ion, with a trend towards smaller radiat ion i ields and a shif i  to lower dose (f ion'r
40 towards 20-24 Gray in involved fields). The use of chemotherapy shifted fiom MOPP
towards the less myelotoxic and leukemoeenic regimens, l ike ABVD and MOPP/ABVD.
Paticnts t.reing cr-rred frorl HL in the 1970s sufl'ered fionr an excess mortality ot 167o
compared with thc general population. Although, the treatment policy appeared to be less
toxic in the 1980s, the exce.s.s mortal i ty decl ined only modestly towards 107n. The excess
nrortal i ty in cured HL patients rvas mainly due to second malignancies and cardiac
cl iseascs. ' Ihe 1O-year cumulative r isk of dying from a (sccond) malignancy decl ined from
79b for patients treated in thc I970s towards 47o for those treatcd in the 1980.s and the
relat ive r isk, compared with mortal i ty in the general populat ion decl ining from 4.3 to 3.0.
The l0-year cumulative incidence for second malignancies halvecl from l07o towards
-59i. The vast majori ty of second sol id turnours appcared in the f icld of previous
irradiat ion. The l0-year r isk of dying from cardiovascular disease bareiy changed t iom
6(% towards 5olo. However, this r isk has decl ined signi l lcantly in the general populat ion,
ascribed to the increascd preventive measLlremcnts and the imprclvement in cardiac care
over the last decacles. For this reason the rclative risk of cardiac death after HL rcmained
unchangccl and was twice compared to the general populat ion. Carcl iac deaths were only
l irund in those patients having received irradiat ion, again undcrscorinq the role o1'
r irdiotherapy in thc development o1'cardiac disease. The preventive rneasurernents and thc
improvcrlents in cardiac care which appcar to be cf l-ect ivc 1br thc gencral populat ion, are
probably' lcss successful in racl iat ion-induced coronary rrtcry discase. Alter f ive years
niorc than one third of survivors from HL suffcr' I'rom onc or more treatment-relatcd
diseascs. Previous radiotherapy appearcd to be ussociatccl with the majol i ty of those
seque ls  o l -wh ich  hypothyro id isn l  was  thc  la r  most  p reva len t .  Secondarv  in fe r t i l i t l 'was
not cvaiuated in this study.
AlthoLrgh incrcasing awilreness appeared to int- lLrence cl inicians towards less toxic
treatment in the 1980s. the late treatment-rclated toxicity lcmainccl substantial.  Cl inical
t l ials of less clamaging trcatment i l re onc ol ' the major goals for irnproving the carc 1br
pat icnrs  w i th  HL.
Prognostic factors are an important tool fbr the predict ion of trcatment-outcome and
sutrseque'nt paticnt-sLrrvival,  Manv prognostic lact()t 's rel lect the biologv of the tunrour
and can theretbre be sccn as epiphenomcna of i ts malignant behar, iour, whe reas patient-
relatcd plognostic factors. such as age, ref lect the f i tness ol-thc patient, including the
abil i t l '  to undcrqo anticancel treatnrent. Thc presence o1'co-nrorbicl i ty appealed to bc an
important patient-rclated prognostic l 'actor in scveral malignancics. In chapter 5. co-
nrorbidrty was prevalent in more than half of al l  unselccted elderlv lyrnphoma patients
(60 years ancl o'ucr ') .  The nrost conrmon co-nrorbid condit ions in HL paticnls u'ere
carcl iovascular diseascs. chronic obstructive lung discases and hvpertension. Thc prescncc
of co-molbicl i ty appeared to be an irnportant contra-incl icat ion l i rr  chcmotherapy, sincc
thc  app l ica t ion  o f  chenro therapv  near lv  h lL lvec l  rn  e ldcr l l 'HL  pa t ien ts  when co-morb id i t l '
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was prcsent. This was associate'd with a l-5!/o [611,s1 overal l  survival in the f irst ul r 'nonths
after diagnosis, a cl i l ' fercnce that is l ikely to increasc after-proloneed lbl low-up. The
presence o1' co-molhiditv apparcntl l '  has a strong aclvcrse impact on survival of FIL
patients. although longcr lbl iorv-up is neccss:rry lbr further proof. Besidcs being a contra
indication co-morbidity may intc-r 'act negatively with chosen treatmcnts. Thc
cornpl icat ion-rate is l ikely to be higher, cspecial ly lbr inl 'ect ior-rs and cardiovascular '
cornpl icat ions. Mot'cover. the rvorsc prognosis in thc prescnce of co-morbidity nray be'
cl irc to the niLtural conrse of the co-morbid condit ion i tsel l ' .  l 'he results of cl inical tr ials
rnav be biased ftrr the cfI 'ect of co-morbidity, causcd by lestr ict ive c' l igibi l i ty cl i ter ia.
nuking their treatnrent results lcss appl icable lor the general health carc' envi lonment.
This was discussed at the fburth International Svmposium on Hodgkin's Lymphonra
fbl lowing the presentation o1'the excel lent results of new chenrotherapv regimens. The
Stanfbrcl V-plotocol and escalatcd BEACOPP, both reeinrens wit lr  a lr igh dose-intensity.
obtained thei l  resr,r l ts in paticnt-groups with a nrl lch lower mcan agc than tbund in thc
gencral popLrlal icln. For this reason those leginrens are l ikel.v to be lcss appl icable in thc
gcncral popLrlat ion, cspecial lv in clderlv pi l t icnts rvith serious co-nrorbiditr ' .  l 'hc
plevalencc o1' co-rnorbici i t l ,  in the general popullr t ion ivi l l  increasc l i rr ther in the near'
frrture causccl bv thc ageing oi the Dutch populat ion and f irr  this rcirson the eff-cct ol 'co
nrorb id i tv  in  c l in ic l l  dcc is ion-mak ing  anc l  surv iva l -ana lvs is  o f  e ldcr ly  HL pa t ien ts  w i l l
qrr in inrportance .
Whether the observccl shi l i  torvalcis less I ' r 'eqLrcnt ldmirt istrat ion o1'chenrothcrlpv in
IJL  pa t ien ts  rv i th  co-nrorb id i ty ' i s . jus t i f i cd  ueeds l 'u r t l i c l  invcs t igu t ion  ar td  cho ice  and dosc
o l  t rea tnren l  in  pa t icn ts  r ,v i th  ser ious  co-morb id i t l ,  shou ld  be  takcn  in to  uceount  in
p fospec t lvc  c l in ica l  t r ia ls .
Drseasc- - r 'e la tcd  pr i lgnos t ic  fac to rs  a le  an  rn rpor tun t  oo l  l i r t  ta i lo t ' ing  o t  t rea tnren t .  [n  thc
prcscncL 'o1 'udvcrsc-  p rognost ic  l ' ac to rs  pa t ien ts  a rc  l i kc l .v  to  p lo l ' i t  fLonr  n r r : r le  in tensrvc
trcatmcnt. Nloreovcr. in thc atrsencc of rdr"crse fr 'ognostic t l rctols a lcss ir t tr :nsivc
t re l r tu ten t  n l r l ' he . jL rs t i f i t -d .  l c lc l ing  to  a  c lec l ine  ln  la tc  t rc r t r ren t - fe la tcc i  n ror ta l i t v  anr l
nrorbicl i ty. The NS sLrhtt,pc is bv far thc most l ' r 'equent histoLogical subtype and rLifccts
pr in ia r i l v  voung pa t ien ts .  For  th is  reuson prognost ic  sub- t1 'p ing  uray  hrvL-  u re l t  in rpae{ .
The B l i t i sh  Nat iona l  L1 'mphonra  I r rves t iga t ion  (BLNI )  g ror . rp  cs tab l i shcc l  a  h is tokrg ica l
g rad ing ' "vh ic l r  appcarec l  to  bc  o f  p rognost ic  s ign i f i cance in  the i r  la rgc  ser ies .  E ,ssent ia l l v
the  sLrh- tvp ing  takcs  rn to  l ccount  the  prc : ;encc  o f  nunrc roL ts  ma l ignant  cc l l s .  thc  i ln ro l l l l t
and  qLra l i t v  o f  f  ib ros is  and the  iu rour ] t  o1 ' the  cc l lu la r  in f i l t ra tc .  Gradc  I l  represcnts  thc
nrorc r lal ignunt vrr l iant. rvi th wursc prognosis ancl is l i rr-rncl in l0-30|i  o1-cases t l  i th NS
tJL .  A l though sevc la l  s tudv-uror . rps  con l ' i lmc t l  the  p lo rnos t ic  re lcvance o1 '  th is  sub-
t1 ,p ing .  rnanv  o thc l  sc l ies  c l id  no t  and sub- typ ing  accor t l rng  to  the  I INLI  rcura ins
c( )n l ro \ rL - rs i ' r l .  In  chapter  6  the  rcsu l ts  o l 'a  s tL rd t 'on  th is  suh- t ,vp ing  o f  pa t ien ts  d ragnosec l
in thc South- [ :ast Nethcrlantls arc prcsentccl.  Ciradc II  NS HL had a signif icrnt a(lvef\c
pfogltost ic intpacf l t l r  paticnts bcing 1r 'eatccl in the 1970s^ r '" ' l i ich rvas inclepenclcnt f i 'onr
o ther  p lognos t ic  fac to ls  a t  n ru l t i v l l i a tc  ana lys is .  Fo l  pa t icn ts  t rca ted  in  the  l9 t i0s  thc
i l3
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survivl l  of grade II  patients improved and equalled the survival of grade I patients.
Likewisc the prc'rgnostic value at multivariate analysis disappeared. Apparently, the more
cffectivc treatment policy in the 1980s has led to thc disappearance of the prognostic
value of sub-typing. This f inding is in accordance with cri t icisms of this sub-
classi l lcat ion that suggested that the use of optimal treatment strategies obviates the
prognostic signi l icance. In our study chemotherapy was ntore f iequently appl ied in grade
II patient.s in the 1980s compaled to the 1970s. This is in accordance with the idea that
gracle l l  morc frcquently presents with occult iLbdominal disease, which wil l  be treated
with systemic chemotherapy but not by irradiat ion. Grade II  NS HL is repclrted to present
morc ft 'e 'quently with consti tut ional B-syrnptoms ancl a raised ESR as was also found in
this study. Both a raised ESR and B-symptoms are used in the prognostic score fbr the
tailoring of treatment in early, stage HL and arc il rcason for the use of systemic
chemotherapy as they have bec-n recogniscd as predictors for occult abdominal disease.
For this renson the application of this tai lored lreatn)ent in the 1980s, advocated by the
EORTC tr ials, has contr ibirted to the disappcarance of thc plognostic signif icance of sub-
classit . icat ion of NS HL.
Sub-classi l lcat ion of NS HL according to the BNLI does not have prognostic value
under contemporary treatment. However, sub-classif icat ion can, among other variables,
bc an important tool lbr tai lor ing trcatment, since i t  ref lects the malignant biology of the
tumour .
Although trL-i i tment is successful fblthe vast rna.jol i tv of HL patients, a subset wi l l  l 'ai l  to
achicve complete rertr isston Llpon treatment with chenrotherapy and subsequently have a
poor sr-rrvival.  Attempts at identi l ' icat ion o1'these patients using histological cr i ter ia have
not becn sr-rccesslul.  In chapter 7 a higher l iequency of Bcl-2 expression in H-RS cel ls
lvas found in the tumours of patients with NS HL who fai led to achieve complete
remission upon primary chenuherapy when comparing with patients who did achieve
completc'  r 'cmission. No dif ference was fbund in Bax-cxpression and prol i ferat ive activi ty
bctween both patient groups. Bcl-2 exprcssion plays an irnportant role in the sensit ivi ty to
chenrothelapy dmts, apalt l iom its role in the pathogenesis of certain malignancies. One
of thc t irnct ions of Bcl- l  is i ts capacity to block ccl l  cleath by binding to and neutral ising
the plo-apoptotic eff 'ects of Bax, a promoter of apoptosis. In dif fuse large cel l  non-
Hodgkirr Ll,mphoma Bcl-2 is f icqucntly cxpressecl and was found to be an independent
predictor l trr  shorter disease-t l 'ee survival.  Likewisc, the H-RS cel ls in HL have been
reportecl to express the Bcl-2 protein and i t  has bccn suggestcd that over-expression is
re la ted  to  c l in ica l  d fug  res is tance.  Bc l -2  i s  known to  inh ib i t  k i l l i ng  by  cy to tox ic  T-ce l l s
bv se ve ral pathways of whrch one is also used by ccltain cytotoxic drugs. The reported
obse-n ,a t ion  t l )a t  n ranv  rc t i va tcc l  cv to tox ic  T  ce l l s  in  thc  v ic in i ty  o f  H-RS ce l l s  i s
russociatcd with a poor prognosis cun be cxplainetl  hy thc incrcase of Bcl-2 levels in the
H-RS.  In  thc  sur round ing  lv rnphocy tes  a  d is t inc t  pa t te rn  o1 'express ion  o f 'Bc l -2  was
obscn'cd. Lymphocytes inrnrcdiately around thc H-RS cel ls expresscd Bcl-2 much less




associated with cl inical drug-resistance. The dccreased expression of Bcl-2 in
lymphocytes in the close vicinity of H-RS cel ls is most l ikely due to the distr-rrbcd
network of cytokines and cel lular act ivat ion. I ts associat ion with cl inical drug resistance
may therefore be a reflection of the severity of distr-rrbance in the cytokine network and
thus be an epiphenomenon of more aggressive biological behaviour. The low levels of
Bcl-2 in conjunction with a frequent expression ofthe pro-apoptotic protein Bax suggests
that many lymphocytes in the vicinity of H-RS cel ls wi l l  go into apoptosis. This is in
accordance with the concept that t issues involved by HL are dependent on a constant
inf lux of circulat ing T lymphocytes. Lymphocytopenia is indeed frequently observed in
the peripheral blood of patients with active disease.
Although the apparent relat ionship between Bcl-2 expression and cl inical drug
resistance in HL in our study cleariy f i t  in the biological conccpt, furthel investigations
should be performed on i ts rel iabi l i ty and whether i t  can be used in cl inical decision
making.
GENERAL CONCLUSION AND PERSPECTIVES
ln the past decades an impt'rrtant improvement in survival of HL patients has been
observed in the populat ion of South-East Netherlands. The treatment st lategies.
developed in clinical trials, appeared to be applicablc for routine cases in the general
health carc environment, provided that qual i ty of care is guarantced by mult idiscipl inary
col laboration. The quali ty of care, as assessed by i ts outcorne, could be achieved in the
prescnce of a good structure (faci l i t ies and equipment) and proccss (activi t ies of health
care providers and their col laboration).r Comprehensive Cancer Centres can ofl 'cr the
fiamework for such col laboration cnabling trcatmcnt-results in community hospitals to
approach results achieved in ref 'erral centrcs.
Of part icular interest is the Iact that elderly patients with HL profi tcd thc most f iom the
improvement in treatment and elderly should be trealed wilh curative intent. However,
adoption of newly developed chemotherapy regimens with high dose intensity, l ikc thc
Stanford V protocoi or escalated BEACOPP, wil l  be hampered by the presence of elderly
with co-morbidity in the general hei i l th care environment. '  '  Co-morbidity is prescnt in
tnore than 507o of unselectcd lynrphonra of 60 years and older and cl inicians l i 'cquently
chose not to give chemothcrapy in thc prcscncc of co-morbidit1,.  The optimal pol icy in
this group of r lat ients wil l  be of growing importancc in thc nelr f l ture duc to thc agcinr
of thc Dutch populat ion. Gr,r idel incs can hclp to dcfinc thc pol icv in incl ividual cascs with
co-rrrorbidity and, prcf 'erahly, co-rnorbici i ty shor-r ld bc takcn into accounl in f ir turc cl inical
t r ia ls .
Cured patients suf ' fer from increased incidence of lethal treatrnent rclatcd diseases. The
awareness of this problcm has emerged since the 1970s ancl is an inccntire tcl  nrinirnisc-
toxicitv o1' treatment. Despite the application of less aggressive treatment, latc toxicity
remains substantial.  Onc of the chal lenges of future treatment strategies is furthcr
i l5
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ref inement of r isk-adapted treatment. Patients l l , i th a high r isk t tr l  treatment-fai lure or
rclapse shoul<l rcccive more intensive init ial  trcatment, whereas low-risk patients wil l
benefi t  l iom less aggressivc treatment tcl  miniruise late toxicity. For patients with st i ige
TA Nodular Lvmphocyte Predominant Hodgkin's l-vmphoma, fbr exarnplc, a wait and see
policy versus standald lrcatment is a su-rgested option. Sincc this is ln i .nf lequent diseirse.
a global col laboration wil l  be necessary to test $,hich option is optirnal."
On the other hand, thc identi f ' icat ion of high-r isk paticnts is di l t ' icult .  The value o1.
histological sub-classif icat ion/grading of thc largest histological group with NS HL
disappeared Llpon more eff-ective treatment. Thc lccently developed prognostic indcx firr
aclvanced HL patients may help clef ine the poor r- isk patients.r Thc poor r isk subgroup
rlef incd by this index howcvcr is small ,  thus requi l ing large prospective tr ials to f ind
optimal trcatnlerl t  pol icy, rvhich might inclucle escalatcd or high-ciose chernotherapv as
init ial  treatnient. Furthermore. the use of imn'Lunohistochemistr\ '  ()r rnolccular nrzLrkcrs
involved in ntult idrug resistance n'ray hclp to del. ine patients with cl inical drug resistarrce.
Since cl inical drug resistance essential ly resides in the resistancc of ccl ls to go into
apoptosis, nralkers involvecl in this proccss arc of interest. lndecd, t l rc highcr cxprcssinn
of  thc  an t i -apopto t ic  p ro tc in  Bc l - l  in  the  H-RS cc l l s  appears  to  bc  assoc ia ted  w i th  worse
p lognos is . ' " ' I l owever ,  fu r thcr  s tudy  on  the  va l i c l i t y  and usef i r lness  as  a  p rognost ic  too l  i s
needed.
Of part iculur interest is thc f inding thi i t  cl inical drug resistancc is inversely rclatecl rvi th
BcL-2 expression in the Th2 lynrphocytcs immediately surroLlnding thc malignant RS
cells. rcf lect ing a more disturbcrl  rnolecular rnicrocnvironmcnt. l lnclcrstanding the
immune-escapL-  ( ) l ' thc  ma l ignant  H-RS cc l l s  w i l l  g ive  poss ib i l i t i es  lb l  thc  dcvc lopmcnt  o l -
irnrnunc therupeutic appnraches. Fol exanrplc. svstcl l ic treatmcnt u, i th bispecif ic
mor roc lo i ra l  an t ibod ies  w i th  an t iscn-spec i f  i c i t_ r ,  ga ins t  C lD3 (on  - l ' - l v rnphocy tes)  and
against CD30 (on Rced-Stcrnberg cel ls) are tcstccl in phasc I/ l l  tr i r ls in rcfractory
pa i i cn ts .  The idea is  to  red i rec t  cy to tox ic  T- lymphocy tes  to  thc  l l 'RS ce l l s  and thus  e l i c i t
an imrnune rcsponse. '  Also, the Lrse of autologous E,tsV-spccif ic cytotoxic T-lymphocytc.s
fbr adoptive i lansler is r-rndercl inici i l  evaluation in a group of paticnts rvith relapsed HL.'
These and otl)L-r iurmune-thcrapv approachcs neecl to l ' re further invcstigated fbr their
ef1icac-"" ancl salcty ancl might gain a placc in either ref lactory pntlcnts as well  as in lorv
risk patients as adjuvant treatrnent in thc context 0f a further minint ised treatment-
stfatesv
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